Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27498434 | 0.98 | TAAR1 (0.54) | TAAR1CHRM2DAOCA12CA1 | |
| SCHEMBL1611321 | 0.93 | TAAR1 (0.54) | TAAR1CHRM2DAOCA12CA1 | |
| SCHEMBL1610409 | 0.91 | TAAR1 (0.52) | TAAR1CHRM2DAOCA12CA1 | |
| SCHEMBL1610545 | 0.91 | TAAR1 (0.52) | TAAR1CHRM2DAOCA12CA1 | |
| SCHEMBL1610239 | 0.91 | TAAR1 (0.52) | TAAR1CHRM2DAOCA12CA1 | |
| SCHEMBL9303855 | 0.91 | TAAR1 (0.52) | TAAR1CHRM2DAOCA12CA1 | |
| SCHEMBL369841 | 0.86 | TAAR1 (0.60) | TAAR1CHRM2DAOCA12CA1 | |
| SCHEMBL6546881 | 0.85 | TAAR1 (0.65) | TAAR1CHRM2DAOCA12CA1 | |
| SCHEMBL6546757 | 0.85 | TAAR1 (0.65) | TAAR1CHRM2DAOCA12CA1 | |
| SCHEMBL8094982 | 0.83 | TAAR1 (0.62) | TAAR1CHRM2DAOCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137851-B | Plasticizer compositions comprising polymeric dicarboxylate and dicarboxylic diester | 巴斯夫欧洲公司 | 2020-10-09 | — | — | CN | claimed |
| EP-0690854-A1 | 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1996-01-10 | — | — | EP | claimed |
| EP-0664802-A1 | N-ARYLHETEROARYLALKYL 1-PHENYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1995-08-02 | — | — | EP | claimed |
| EP-0234944-A1 | Insecticidal N'-substituted-N-acyl-N'-alkylcarbonylhydrazines | ROHM AND HAAS COMPANY (US) | 1987-09-02 | — | — | EP | claimed |
| US-20230018615-A1 | STEROIDS AND METHODS OF MANUFACTURE | TRUSTEES OF DARTMOUTH COLLEGE | 2023-01-19 | — | — | US | disclosed |
| CN-115197139-A | Preparation method of roxasistat and intermediate thereof | 南京方生和医药科技有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-114551770-A | Organic electroluminescent device | 固安鼎材科技有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3153023-B1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2022-03-16 | — | — | EP | disclosed |
| US-20210253566-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. | 2021-08-19 | — | — | US | disclosed |
| CN-112961149-A | Cytochrome P450 inhibitors and uses thereof | 安吉恩生物医药公司 | 2021-06-15 | — | — | CN | disclosed |
| US-20210171515-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP. | 2021-06-10 | — | — | US | disclosed |
| EP-3180335-B1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | ANGION BIOMEDICA CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0318893-A2 | Titanocenes, their use and N-substituted fluoroanilines | CIBA-GEIGY AG (CH) | 1989-06-07 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
| US-4559083-A | CONTROLLING MONO-AND DICOTYLEDONOUS WEEDS USING A MIXTURE ALSO INCLUDING A DILUENT AND SURFACTANT | ESZAKMAGYARORSZAGI VEGYIMUVEK (HU) | 1985-12-17 | — | — | US | disclosed |
| EP-0054132-B1 | PYRIMIDONES, THEIR PREPARATION AND MEDICINES CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1984-10-10 | — | — | EP | disclosed |
| US-4379788-A | HYPOTENSIVES, ANTIARRHYTHMIA, B-BLOCKERS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-04-12 | — | — | US | disclosed |
| EP-0054132-A1 | Pyrimidones, their preparation and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1982-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171515-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | CYP7A1, CYP2E1, CYP11B1 | TAAR1 3430/4885CHRM2 3225/4885DAO 1665/4885 |
| US-20230018615-A1 | STEROIDS AND METHODS OF MANUFACTURE | HSD17B7, HSD11B1, HSD11B2 | TAAR1 1654/4885CHRM2 4777/4885DAO 3532/4885 |
| US-20210253566-A1 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | CYP7A1, CYP2E1, CYP1A2 | TAAR1 3292/4885CHRM2 3204/4885DAO 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.